Loading...
•
Jun 30, 2024
Cocrystal Pharma Q2 2024 Earnings Report
Cocrystal Pharma reported financial results for Q2 2024 and provided updates on its antiviral drug-development programs.
Key Takeaways
Cocrystal Pharma reported a net loss of $5.3 million, or $0.54 per share, for the second quarter of 2024. The company's R&D expenses increased due to the advancement of CC-42344 and CDI-988 into clinical studies. They expect their cash to be sufficient to advance planned development programs through the coming 12 months.
Phase 2a study with PB2 inhibitor CC-42344 topline results expected, including initial indication of virology in humans infected with influenza A virus.
Plan to file an Investigational New Drug (IND) application in 2025 to conduct next study in the U.S. for CC-42344.
Preparing to initiate a Phase 1 study in healthy volunteers to evaluate inhaled CC-42344 as a potential prophylactic and therapeutic for influenza A.
Preparations underway to begin the multiple-ascending dose portion of the first-in-human study with pan-norovirus/pan-coronavirus oral protease inhibitor CDI-988.
Forward Guidance
Cocrystal Pharma expects its cash to be sufficient to advance planned development programs through the coming 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...